{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:28:01Z","timestamp":1751873281340,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"DOI":"10.1182\/blood.2022016274","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T15:33:08Z","timestamp":1655393588000},"page":"3563-3564","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Smart salvage treatment for Hodgkin lymphoma"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-4974","authenticated-orcid":false,"given":"Peter W. M.","family":"Johnson","sequence":"first","affiliation":[{"name":"University of Southampton"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"25","key":"2022062315232291200_B1","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood."},{"issue":"15","key":"2022062315232291200_B2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","article-title":"Optimizing therapy in advanced-stage Hodgkin lymphoma","volume":"131","author":"Lim","year":"2018","journal-title":"Blood."},{"issue":"8852","key":"2022062315232291200_B3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet."},{"issue":"12","key":"2022062315232291200_B4","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol."},{"issue":"2","key":"2022062315232291200_B5","first-page":"467","article-title":"Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin\u2019s disease in relapse or failure after initial chemotherapy: results of the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte H89 Trial","volume":"20","author":"Ferm\u00e9","year":"2002","journal-title":"J Clin Oncol."},{"issue":"34","key":"2022062315232291200_B6","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022062315232291200_B7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol."},{"issue":"4","key":"2022062315232291200_B8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol."},{"issue":"3","key":"2022062315232291200_B9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol."},{"issue":"25","key":"2022062315232291200_B10","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/25\/3563\/1903546\/bloodbld2022016274c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/25\/3563\/1903546\/bloodbld2022016274c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T15:24:14Z","timestamp":1655997854000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/25\/3563\/485575\/Smart-salvage-treatment-for-Hodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":10,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016274","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}